Royalty Pharma
RPRX
199 hedge funds and large institutions have $13.3B invested in Royalty Pharma in 2020 Q4 according to their latest regulatory filings, with 94 funds opening new positions, 70 increasing their positions, 24 reducing their positions, and 27 closing their positions.
248% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 27
192% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 24
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
62% more capital invested
Capital invested by funds: $8.19B → $13.3B (+$5.1B)
49% more funds holding
Funds holding: 134 → 199 (+65)
15.75% more ownership
Funds ownership: 43.53% → 59.28% (+16%)
54% less call options, than puts
Call options by funds: $18.1M | Put options by funds: $39.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$612M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$287M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$258M |
| 4 |
BlackRock
New York
|
+$226M |
| 5 |
CCM
CAAS Capital Management
New York
|
+$153M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$310M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$213M |
| 3 |
BL
Bleichroeder LP
New York
|
-$38.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$26.4M |
| 5 |
Blackstone Inc
New York
|
-$15.3M |
RPRX Hedge Fund Activity: Q4 2020 in Review
199 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q4 2020, worth a combined $13.3B — up 62% from $8.19B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new RPRX positions and 27 closed out — a net gain of 67 holders — while 70 added to existing stakes and 24 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $612M. The largest seller was Adage Capital Partners, cutting an estimated $310M.
- 199 institutional investors held Royalty Pharma (RPRX) as of Q4 2020, up from 134 in Q3 2020.
- Funds reported $13.3B of Royalty Pharma stock for Q4 2020, up 62% quarter-over-quarter.
- 94 funds opened new Royalty Pharma positions in Q4 2020 and 27 closed out, a net change of +67 holders.
- The largest Royalty Pharma buyer in Q4 2020 was Morgan Stanley, an estimated $612M added.
- The largest Royalty Pharma seller in Q4 2020 was Adage Capital Partners, an estimated $310M sold.
Based on aggregated 13F filings for Q4 2020.